Cardiovascular Disease Incidence and Risk Mitigation in Patients with Locally Advanced or Metastatic Prostate Cancer on ADT

Expert perspectives on the risk of cardiovascular disease as it exists in the context of androgen deprivation therapy (ADT) and prostate cancer.

Shared insight on a timeline of clinical studies contextualizing cardiovascular disease in the setting of prostate cancer management.

Comprehensive insight regarding strategies to mitigate cardiovascular risk in patients on therapy for prostate cancer.

Centering focus on a patient case of cardiovascular risk and prostate cancer, experts share their perspective on management strategies.

Oncologist Joelle Hamilton, MD, shares her perspective on the typical patient with prostate cancer seen at her institution.

Urologist David Morris, MD, FACS, defines the typical patient with prostate cancer treated at his practice.

Cardiologist Anees A. Daud, MD, breaks down the typical patient with prostate cancer seen at his practice.

Expert perspectives on strategies to optimize communication, both between healthcare professionals and with patients who present with prostate cancer.

Direct insight from a cardiologist on the advent of cardiovascular risk when treating a patient for prostate cancer.

Medical oncologist Joelle Hamilton, MD, reflects on the prevalence of cardiovascular risk while managing prostate cancer in patients.

Cardiologist Anees A. Daud, MD, elucidates examinations and tests that help to identify cardiovascular risk in practice.

Expert perspectives on the typical patient workup that occurs in oncology practice to identify cardiovascular risk.

Insight is provided on strategies that may be employed to mitigate cardiovascular risk in patients receiving care for prostate cancer.

Urologist David Morris, MD, FACS, shares his perspective on communicating cardiovascular risk to patients starting androgen deprivation therapy.

Urologist David Morris, MD, FACS, shares his perspective on communicating cardiovascular risk to patients starting androgen deprivation therapy.

Expert insight on selection of androgen deprivation therapy and how related adverse events may be communicated to patients in advance.

David Morris, MD, FACS, shares advice on followup with patients on androgen deprivation therapy for prostate cancer.

Cardiologist Anees A. Daud, MD, highlights how a cardiologist may followup with patients receiving androgen deprivation therapy and how multidisciplinary care plays a role in this setting.

Insight from Urologist David Morris, MD, FACS, as he reacts to the educational video from AbbVie on cardiovascular risk and androgen deprivation therapy.

Insight from cardiologist Anees A. Daud, MD, following his viewing of AbbVie’s educational video on cardiovascular risk and androgen deprivation therapy.